Postpartum depression screening: what the evidence supports

Federal guidance has told primary care and ob-gyn practices to screen every pregnant and postpartum patient for depression since 2016, and the 2023 update from the U.S. Preventive Services Task Force still sets no required interval past that one screen. What actually changed the practical answer is coverage, not clinical guidance: as of July 2026, every state except Arkansas pays for a full 12 months of postpartum Medicaid, replacing the 60-day cutoff that used to end most patients’ coverage right around when the traditional six-week visit happened. That gives a practice a full year to build a screening cadence around, instead of the single appointment insurance used to allow.

The six-week check misses most of the postpartum year

For decades, the standard postpartum visit has been a single appointment sometime between four and six weeks after birth, and ACOG’s committee opinion on postpartum care names the flaw directly: as many as 40% of patients never attend it at all. For the patients who do show up, that visit is often the only structured check-in on mood and mental health in the entire first year, even though a CDC analysis of 2018 Pregnancy Risk Assessment Monitoring System (PRAMS) data found postpartum depressive symptoms in 13.2% of respondents nationally — a figure that ranged from 9.7% to 23.5% depending on which of the 31 participating sites was reporting. That spread matters more than the national average: a screening plan built around one visit performs very differently in a site where roughly one in ten patients is symptomatic than in one where it is closer to one in four.

ACOG’s own answer, laid out in the same committee opinion, is to stop treating postpartum care as a single encounter. It calls for an initial contact — in person or by phone — within the first three weeks after birth, followed by a comprehensive visit no later than 12 weeks, with mood and emotional well-being screened using a validated instrument at that visit. The organization frames the whole stretch as a “fourth trimester,” language chosen specifically to push practices away from treating six weeks as the point where recovery, and the risk that comes with it, is considered settled.

Federal guidance says screen — it doesn’t say how often

The Task Force’s Grade B recommendation explicitly names pregnant and postpartum patients as part of the population practices should screen, but it stops short of prescribing a schedule. The recommendation states plainly that reviewers “found no evidence on the optimal frequency of screening for depression,” which leaves a practice to decide on its own whether a positive screen at three weeks warrants a repeat check at three months, at six months, or only whenever the next unrelated visit happens to land.

That silence is exactly where ACOG’s structure, and separately the government’s own mortality data, become more useful than the federal recommendation on its own. CDC’s review of state Maternal Mortality Review Committee findings from 2020 attributed 22.5% of pregnancy-related deaths across 38 states to a mental health condition — more than any other single underlying cause — and judged 84% of the deaths reviewed to have been preventable. Mortality review windows extend a full year after birth, not 12 weeks, which is a reasonable argument for treating ACOG’s comprehensive visit as a floor for screening rather than the end of it.

Medicaid’s coverage window used to end before the risk did

Coverage, more than clinical guidance, is what actually forced practices to rethink the postpartum calendar. Federal law long required Medicaid — the payer behind roughly four in ten U.S. births — to cover pregnancy-related care only through 60 days postpartum, a cutoff that could lapse before ACOG’s own 12-week comprehensive visit, let alone anything scheduled after it. The American Rescue Plan Act of 2021 gave states a new option, effective April 2022, to extend that window to a full 12 months through a state plan amendment; the Consolidated Appropriations Act of 2023 then made the option a permanent part of Medicaid law rather than a five-year pilot, according to KFF’s tracker of state action.

Adoption has been fast but not universal. Georgetown University’s Center for Children and Families reported that 48 states and Washington, D.C. adopted the 12-month extension between 2021 and 2025, with Wisconsin’s Assembly voting 95-1 in February 2026 to join them. KFF’s own tracker, updated in July 2026, confirms Wisconsin’s extension took effect July 1, 2026 — which leaves Arkansas as the only state that has not extended postpartum Medicaid coverage past the original 60-day limit. For a practice serving a Medicaid population almost anywhere else in the country, a depression screen scheduled for month six or month nine is no longer a service the payer will have already stopped covering by the time the appointment happens.

A longer coverage window still needs a follow-up structure

None of this changes the work of actually getting a postpartum patient back in front of a provider. ACOG’s own data on return-to-work timing helps explain why that work is harder than it sounds: 23% of employed patients return to work within 10 days of birth, and another 22% return between 10 and 40 days, meaning a large share of the population a practice is trying to screen is also newly navigating child care, a job, and disrupted sleep in the exact window a follow-up visit needs to be scheduled. A payer that now covers month six or month nine does nothing about a no-show at month six or month nine.

That gap is one a screening cadence has to close on its own, since neither the Task Force nor ACOG specifies what should happen between the 12-week comprehensive visit and the end of a now much longer Medicaid coverage window. A practice that manages every postpartum contact — the three-week check-in, the twelve-week visit, and whatever comes after — as its own tracked list, rather than folding it into general appointment recall, is the one actually using the extra months of coverage the payer now provides.

Where the guidance conflicts — and what a practice should document

Three authorities now sit on the same chart without saying the same thing. The USPSTF says screen pregnant and postpartum patients and gives a Grade B recommendation, but states it found no evidence on optimal screening frequency (USPSTF). ACOG supplies a structure — contact within three weeks, comprehensive visit by 12 weeks, validated mood screen at that visit — without prescribing what happens at month six or nine (ACOG). CDC maternal mortality review data extend the risk window to a full year after birth and attribute 22.5% of pregnancy-related deaths in 38 states (2020) to a mental health condition, with 84% of reviewed deaths judged preventable (CDC).

None of those three documents is “wrong.” They answer different questions: whether to screen, how to structure early postpartum care, and how long the mortality risk window lasts. The operational mistake is to treat the Task Force’s silence on frequency as permission to stop at six weeks, or to treat ACOG’s 12-week visit as the end of the story when Medicaid now pays through month twelve in 48 states and D.C. The honest internal policy names all three: USPSTF as the screening mandate, ACOG as the early-postpartum floor, and the MMRC year as the reason to schedule at least one later recheck for anyone who screened positive — or for anyone who never made the six-week visit at all, given ACOG’s figure that as many as 40% skip it.

PRAMS adds a fourth caution: the national 13.2% with postpartum depressive symptoms sat inside a site range of 9.7% to 23.5% (CDC/PRAMS via PMC). A cadence copied from a national average will under-serve a site at the high end of that range. Measure your own positive-screen rate for one quarter before you decide how aggressive the month-six and month-twelve pulls need to be.

Checklist: year-long postpartum screening without a second charting system

1. At discharge or the first postpartum contact: schedule the ≤3-week check and the ≤12-week comprehensive visit; capture TCPA consent that explicitly covers outreach through 12 months postpartum.
2. At the comprehensive visit: administer a validated instrument; if positive, place a referral the same day with a signed release moving with it.
3. For positive screens (and for no-shows to the six-week visit): create a tracked list with month-6 and month-12 recheck dates, owned by a named staff member — not folded into generic recall.
4. Around month 6: re-verify Medicaid eligibility in extension states rather than assuming the old 60-day cutoff; Arkansas remains the holdout past 60 days per Georgetown and KFF.
5. Before each outreach wave: confirm consent language still matches the channel and the time window you are about to use.

What your practice can do

• Build a screening cadence that runs past 12 weeks. ACOG’s own schedule stops prescribing timing at the comprehensive visit; extend it with a scheduled recheck at 6 and 12 months for anyone who screened positive earlier, instead of waiting for an unrelated visit to raise it again.
• Verify coverage mid-year, not just at intake. In the jurisdictions where Medicaid now runs 12 months postpartum, confirm eligibility again around month six rather than assuming the old 60-day cutoff still applies — a stale assumption from before 2022 is enough to talk a practice out of billing a visit the payer will actually cover.
• Treat postpartum follow-up as its own no-show risk. A patient newly back at work or without settled child care needs a different reminder cadence than a routine annual visit; folding both into one workflow is how postpartum slots quietly go empty.
• Extend consent along with the coverage window. If reminder calls and texts now reach out to month nine or month twelve, the TCPA consent captured at intake should say so explicitly — enrollment-era consent language shouldn’t be stretched to cover outreach a year later without being checked.
• Move referrals the same day, paperwork attached. A positive screen that leads to a referral for behavioral health care needs a HIPAA-compliant release moving with it immediately; a referral slip without the authorization is a dead end for both providers.
• Document which authority each step follows. USPSTF for the decision to screen, ACOG for the early visits, your own protocol for month 6/12 — so staff are not improvising from three conflicting PDFs.

If your practice is building this kind of year-long follow-up on top of the broader scheduling and consent rules that already apply to phone and messaging in the United States, that overlaps directly with how those rules apply to a practice’s day-to-day operations.